Insider transactions

James N Topper

CIK 1341382 · last filed 2026-05-21

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$998.89M
Companies
17
Total Filings
114
Lifetime Open-Market Net
$281.48M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

PHAT price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
550 HAMILTON AVENUE, SUITE 100
PALO ALTO, CA 94301
Related Filers
Patrick J Heron — 23 joint filings, latest 2025-09-30
ANAPTYSBIO, INC — 11 joint filings, latest 2023-01-10
FHMLS X, L.L.C. — 11 joint filings, latest 2025-09-30
Frazier Life Sciences X, L.P. — 11 joint filings, latest 2025-09-30
FHMLS IX, L.L.C. — 9 joint filings, latest 2020-10-20
Frazier Life Sciences IX, L.P. — 9 joint filings, latest 2020-10-20
FHM LIFE SCIENCES VIII, L.L.C. — 8 joint filings, latest 2023-10-26
Frazier Life Sciences VIII, L.P. — 8 joint filings, latest 2023-10-26
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PHAT Director 126,121 $5.94 $749.2K $100.19M 10 2026-05-21
NAMSW Director 3,801,000 $8.25 $31.36M $586.2K 8 2025-09-17
MBX 10%+ Owner 4,552,774 $50.29 $228.96M $40.00M 1 2024-09-17
ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted Director 1,371,450 $64.97 $89.10M $2.00M 13 2024-05-20
HilleVax, Inc. (HLVX) Delisted 10%+ Owner 8,544,187 $2.09 $17.86M $641.6K 1 2024-04-08
ANAB Director 280,341 $48.77 $13.67M $6.00M 10 2023-01-10
Allena Pharmaceuticals, Inc. (ALNA) Delisted Director 1,466,805 $0.07 $110.0K $7.00M 4 2020-11-18
Aptinyx Inc. (APTX) Delisted Director 3,195,055 $0.06 $194.9K $2.40M 7 2020-04-02
PASG 10%+ Owner 148,862 $3.36 $500.0K $39.60M 1 2020-03-03
MIRM 10%+ Owner 3,116,912 $83.27 $259.55M $27.00M 1 2019-07-24
Entasis Therapeutics Holdings Inc. (ETTX) Delisted Director 337,707 $2.19 $739.6K $5.64M 2 2019-01-22
Sierra Oncology, Inc. (SRRA) Delisted Director 148,148 $54.99 $8.15M $8.00M 1 2017-02-16
Sierra Oncology, Inc. (DNAI) Delisted Director 1,966,195 — — $3.74M 2 2016-06-20
GKOS 10%+ Owner 2,603,362 $178.27 $464.10M $0 1 2015-06-30
AMICUS THERAPEUTICS, INC. (FOLD) Delisted Director 907,464 $14.49 $13.15M $34.05M 46 2013-06-17
PORTOLA PHARMACEUTICALS INC (PTLA) Delisted Director 7,252 — — $0 2 2013-06-07
LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Director 84,214 $6.22 $523.8K $4.63M 4 2009-02-26

Recent Filings · Page 4 of 12

114 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-11-18 Allena Pharmaceuticals, Inc. (ALNA) Delisted Grant (A) — $0 EDGAR
2020-05-22 PHAT Grant (A) — $0 EDGAR
2020-04-02 Aptinyx Inc. (APTX) Delisted Grant (A) +4,976 $10.7K EDGAR
2020-03-03 PASG Mixed +20,036,876 $39.60M EDGAR
2020-02-13 ANAB Grant (A) — $0 EDGAR
2020-01-06 ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted Grant (A) — $0 EDGAR
2020-01-03 Aptinyx Inc. (APTX) Delisted Grant (A) — $0 EDGAR
2019-10-30 PHAT Mixed +12,031,355 $202.88M EDGAR
2019-10-02 Aptinyx Inc. (APTX) Delisted Grant (A) — $0 EDGAR
2019-07-24 MIRM Mixed +14,267,648 $27.00M EDGAR
Showing 31–40 of 114
Page 4 of 12
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.